Cargando…

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

Detalles Bibliográficos
Autores principales:	Bridgewater, John, Lopes, Andre, Beare, Sandra, Duggan, Marian, Lee, Dymphna, Ricamara, Maravic, McEntee, Delyth, Sukumaran, Ajithkumar, Wasan, Harpreet, Valle, Juan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916533/ https://www.ncbi.nlm.nih.gov/pubmed/27328670 http://dx.doi.org/10.1186/s12885-016-2403-1

Ejemplares similares

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
por: Valle, Juan W, et al.
Publicado: (2015)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018)

PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer
por: Pereira, Stephen P, et al.
Publicado: (2018)

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
por: McNamara, Mairéad Geraldine, et al.
Publicado: (2017)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Quality of life, long-term survivors and long-term outcome from the ABC-02 study
por: Bridgewater, John, et al.
Publicado: (2016)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
por: Lamarca, Angela, et al.
Publicado: (2021)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2016)

Anthropometric Variables Accurately Predict Dual Energy X-Ray Absorptiometric-Derived Body Composition and Can Be Used to Screen for Diabetes
por: Yavari, Reza, et al.
Publicado: (2011)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Reproductive pathology of domestic mammals /
por: McEntee, Kenneth
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_p290cu2f5ugrslolj91les6cj3